MAIA Biotechnology (NYSEAMERICAN:MAIA) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

MAIA Biotechnology (NYSEAMERICAN:MAIA) announced its quarterly earnings data on Monday. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01, FiscalAI reports.

MAIA Biotechnology Trading Up 1.9%

Shares of NYSEAMERICAN MAIA opened at $1.07 on Wednesday. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $3.19. The stock has a market cap of $66.06 million, a PE ratio of -2.29 and a beta of 0.28. The company has a 50-day moving average of $1.20 and a 200 day moving average of $1.43.

Insider Buying and Selling

In other MAIA Biotechnology news, CEO Vlad Vitoc bought 73,000 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were acquired at an average cost of $1.37 per share, with a total value of $100,010.00. Following the purchase, the chief executive officer directly owned 1,049,121 shares of the company’s stock, valued at $1,437,295.77. This trade represents a 7.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ramiro Guerrero bought 78,239 shares of the stock in a transaction dated Thursday, August 27th. The shares were bought at an average price of $1.39 per share, for a total transaction of $108,752.21. Following the completion of the acquisition, the director owned 689,081 shares in the company, valued at approximately $957,822.59. The trade was a 12.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 258,078 shares of company stock worth $352,426 over the last three months. Corporate insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells. MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.